' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID


Gewähltes Keyword: multiple sclerosis

Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting.
Seiberl, M; Feige, J; Hilpold, P; Hitzl, W; Machegger, L; Buchmann, A; Khalil, M; Trinka, E; Harrer, A; Wipfler, P; Moser, T;
Int J Mol Sci. 2023; 24(4):
Originalarbeiten (Zeitschrift)
The Use of Kappa Free Light Chains to Diagnose Multiple Sclerosis
Arneth, B; Kraus, J
MEDICINA-LITHUANIA. 2022; 58(11): 1512
Experimental laboratory biomarkers in multiple sclerosis.
Arneth, B; Kraus, J;
Wien Med Wochenschr. 2022; 172(15-16): 346-358.
Myelinated axons are the primary target of hemin-mediated oxidative damage in a model of the central nervous system.
Baldacchino, K; Peveler, WJ; Lemgruber, L; Smith, RS; Scharler, C; Hayden, L; Komarek, L; Lindsay, SL; Barnett, SC; Edgar, JM; Linington, C; Thummler, K
EXP NEUROL. 2022; 354: 114113
Originalarbeiten (Zeitschrift)
Long-term outcome after COVID-19 infection in multiple sclerosis: a nation-wide multicenter matched-control study.
Bsteh, G; Assar, H; Gradl, C; Heschl, B; Hiller, MS; Krajnc, N; Di Pauli, F; Hegen, H; Traxler, G; Leutmezer, F; Wipfler, P; Zulehner, G; Guger, M; Enzinger, C; Berger, T;
Eur J Neurol. 2022;
Originalarbeiten (Zeitschrift)
Impact of vaccination on COVID-19 outcome in multiple sclerosis.
Bsteh, G; Gradl, C; Heschl, B; Hegen, H; Di Pauli, F; Assar, H; Leutmezer, F; Traxler, G; Krajnc, N; Zulehner, G; Hiller, MS; Rommer, P; Wipfler, P; Guger, M; Enzinger, C; Berger, T;
Eur J Neurol. 2022;
Originalarbeiten (Zeitschrift)
Humoral Response to SARS-CoV-2 Antigen in Patients Treated with Monoclonal Anti-CD20 Antibodies: It Is Not All about B Cell Recovery.
Feige, J; Berek, K; Seiberl, M; Hilpold, P; Hitzl, W; Di Pauli, F; Hegen, H; Deisenhammer, F; Trinka, E; Harrer, A; Wipfler, P; Moser, T;
Neurol Int. 2022; 14(4): 943-951.
Originalarbeiten (Zeitschrift)
Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data
Hauer, L; Sellner, J
DRUG DES DEV THER. 2022; 16: 3915-3927.
Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study.
Moser, T; OSullivan, C; Otto, F; Hitzl, W; Pilz, G; Schwenker, K; Mrazek, C; Haschke-Becher, E; Trinka, E; Wipfler, P; Harrer, A;
Ther Adv Neurol Disord. 2022; 15: 17562864221092092
Originalarbeiten (Zeitschrift)
Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications - A pilot study.
Moser, T; Otto, F; OSullivan, C; Hitzl, W; Pilz, G; Harrer, A; Trinka, E; Wipfler, P;
Mult Scler Relat Disord. 2022; 59: 103560
Originalarbeiten (Zeitschrift)
Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety.
Moser, T; Ziemssen, T; Sellner, J;
Wien Med Wochenschr. 2022; 172(15-16):365-372
Originalarbeiten (Zeitschrift)
Brutonxxxs Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis
Steinmaurer, A; Wimmer, I; Berger, T; Rommer, PS; Sellner, J
CURR PHARM DESIGN. 2022; 28(6): 437-444.
The TRACK-MS Test Battery: A Very Brief Tool to Track Multiple Sclerosis-Related Cognitive Impairment
Taranu, D; Tumani, H; Holbrook, J; Tumani, V; Uttner, I; Fissler, P
BIOMEDICINES. 2022; 10(11): 2975
Originalarbeiten (Zeitschrift)
COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry.
Bsteh, G; Assar, H; Hegen, H; Heschl, B; Leutmezer, F; Di Pauli, F; Gradl, C; Traxler, G; Zulehner, G; Rommer, P; Wipfler, P; Guger, M; Enzinger, C; Berger, T;
PLoS One. 2021; 16(7): e0255316
Originalarbeiten (Zeitschrift)
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.
Bsteh, G; Durauer, S; Assar, H; Hegen, H; Heschl, B; Leutmezer, F; Di Pauli, F; Gradl, C; Traxler, G; Zulehner, G; Rommer, P; Wipfler, P; Guger, M; Hoftberger, R; Enzinger, C; Berger, T
Mult Scler. 2021; 27(14):2209-2218
Originalarbeiten (Zeitschrift)
Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry.
Guger, M; Enzinger, C; Leutmezer, F; Di Pauli, F; Kraus, J; Kalcher, S; Kvas, E; Berger, T
J Neurol. 2021; 268(11):4303-4310
Originalarbeiten (Zeitschrift)
A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications.
Hauer, L; Perneczky, J; Sellner, J
J Neurol. 2021; 268(11):4066-4077
Cardiovascular fingolimod effects on rapid baroreceptor unloading are counterbalanced by baroreflex resetting.
Hilz, MJ; Roy, S; Leal, CD; Liu, M; Canavese, F; Winder, K; Hoesl, KM; Lee, DH; Linker, RA; Wang, RH
NEUROL SCI. 2021; 42(1): 111-121.
Originalarbeiten (Zeitschrift)
A R-Script for Generating Multiple Sclerosis Lesion Pattern Discrimination Plots
Marschallinger, R; Tur, C; Marschallinger, H; Sellner, J
BRAIN SCI. 2021; 11(1): 90
Originalarbeiten (Zeitschrift)
Cladribine Alters Immune Cell Surface Molecules for Adhesion and Costimulation: Further Insights to the Mode of Action in Multiple Sclerosis.
Moser, T; Hoepner, L; Schwenker, K; Seiberl, M; Feige, J; Akgün, K; Haschke-Becher, E; Ziemssen, T; Sellner, J;
Cells. 2021; 10(11):
Originalarbeiten (Zeitschrift)
Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy.
Moser, T; OSullivan, C; Puttinger, C; Feige, J; Pilz, G; Haschke-Becher, E; Cadamuro, J; Oberkofler, H; Hitzl, W; Harrer, A; Kraus, J; Trinka, E; Wipfler, P;
Biomedicines. 2021; 9(11):
Originalarbeiten (Zeitschrift)
Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients.
Moser, T; Seiberl, M; Feige, J; Bieler, L; Radlberger, RF; OSullivan, C; Pilz, G; Harrer, A; Schwenker, K; Haschke-Becher, E; Machegger, L; Grimm, J; Redlberger-Fritz, M; Buchmann, A; Khalil, M; Kvas, E; Trinka, E; Wipfler, P;
Front Immunol. 2021; 12:718895
Originalarbeiten (Zeitschrift)
Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine.
Radlberger, RF; Sakic, I; Moser, T; Pilz, G; Harrer, A; Wipfler, P;
Mult Scler Relat Disord. 2021; 48:102727
Originalarbeiten (Zeitschrift)
Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies.
Seliner, J; Rommer, PS
VACCINES-BASEL. 2021; 9(2):
Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease.
Berger, T; Adamczyk-Sowa, M; Csepany, T; Fazekas, F; Fabjan, TH; Horakova, D; Ledinek, AH; Illes, Z; Kobelt, G; Jazbec, SS; Klimova, E; Leutmezer, F; Rejdak, K; Rozsa, C; Sellner, J; Selmaj, K; Stourac, P; Szilasiova, J; Turcani, P; Vachova, M; Vaneckova, M; Vecsei, L; Havrdova, EK
THER ADV NEUROL DISO. 2020; 13: 1756286420975223
Vitamin D Supplementation in Multiple Sclerosis: A Critical Analysis of Potentials and Threats.
Feige, J; Moser, T; Bieler, L; Schwenker, K; Hauer, L; Sellner, J;
Nutrients. 2020; 12(3):
Delayed high-grade atrioventricular block requiring pacemaker implantation in a multiple sclerosis patient treated with fingolimod.
Feige, J; Schernthaner, C; Wipfler, P; Sellner, J;
Mult Scler Relat Disord. 2020; 38: 101515
Cardiac Autonomic Dysfunction in Multiple Sclerosis: A Systematic Review of Current Knowledge and Impact of Immunotherapies.
Findling, O; Hauer, L; Pezawas, T; Rommer, PS; Struhal, W; Sellner, J
J CLIN MED. 2020; 9(2):
Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
Guger, M; Enzinger, C; Leutmezer, F; Kraus, J; Kalcher, S; Kvas, E; Berger, T
J NEUROL. 2020; 267(7): 2090-2100.
Originalarbeiten (Zeitschrift)
[Surgical decompression of the peroneal nerve at the level of the fibular head].
Heinrich, K; Pumberger, P; Schwaiger, K; Schaffler, G; Hladik, M; Wechselberger, G;
Oper Orthop Traumatol. 2020; 32(5):467-474
Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018).
Lefaucheur, JP; Aleman, A; Baeken, C; Benninger, DH; Brunelin, J; Di Lazzaro, V; Filipović, SR; Grefkes, C; Hasan, A; Hummel, FC; Jääskeläinen, SK; Langguth, B; Leocani, L; Londero, A; Nardone, R; Nguyen, JP; Nyffeler, T; Oliveira-Maia, AJ; Oliviero, A; Padberg, F; Palm, U; Paulus, W; Poulet, E; Quartarone, A; Rachid, F; Rektorová, I; Rossi, S; Sahlsten, H; Schecklmann, M; Szekely, D; Ziemann, U;
Clin Neurophysiol. 2020; 131(2):474-528
Aging and Neurodegenerative Disease: Is the Adaptive Immune System a Friend or Foe?
Mayne, K; White, JA; McMurran, CE; Rivera, FJ; de la Fuente, AG
FRONT AGING NEUROSCI. 2020; 12: 572090
The role of TH17 cells in multiple sclerosis: Therapeutic implications.
Moser, T; Akgün, K; Proschmann, U; Sellner, J; Ziemssen, T;
Autoimmun Rev. 2020; 19(10):102647
Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS.
Moser, T; Schwenker, K; Seiberl, M; Feige, J; Akgün, K; Haschke-Becher, E; Ziemssen, T; Sellner, J;
Ann Clin Transl Neurol. 2020; 7(11):2199-2212
Originalarbeiten (Zeitschrift)
Successful disease control with alemtuzumab in MOG-IgG-associated demyelinating disease with MS-phenotype.
Otto, F; Moser, T; Feige, J; Seiberl, M; Bieler, L; Sellner, J;
Mult Scler Relat Disord. 2020; 42: 102108
Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic review.
Sellner, J; Rommer, PS
AUTOIMMUN REV. 2020; 19(4): 102492
Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study.
Auer, M; Hegen, H; Sellner, J; Oppermann, K; Bsteh, G; Di Pauli, F; Berger, T; Deisenhammer, F
BRAIN BEHAV. 2019; 9(7): e01332
Originalarbeiten (Zeitschrift)
Do elevated autoantibodies in patients with multiple sclerosis matter?
Dal-Bianco, A; Wenhoda, F; Rommer, PS; Weber, M; Altmann, P; Kraus, J; Leutmezer, F; Salhofer-Polanyi, S;
Acta Neurol Scand. 2019; 139(3):238-246
Originalarbeiten (Zeitschrift)
Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: A note of caution.
Feige, J; Salmhofer, H; Hecker, C; Kunz, AB; Franzen, M; Moré, E; Sellner, J;
Mult Scler. 2019; 25(9): 1326-1328.
Real-life use of oral disease-modifying treatments in Austria.
Guger, M; Enzinger, C; Leutmezer, F; Kraus, J; Kalcher, S; Kvas, E; Berger, T
ACTA NEUROL SCAND. 2019; 140(1): 32-39.
Originalarbeiten (Zeitschrift)
Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry.
Guger, M; Enzinger, C; Leutmezer, F; Kraus, J; Kalcher, S; Kvas, E; Berger, T
J NEUROL. 2019; 266(11): 2672-2677.
Originalarbeiten (Zeitschrift)
High dose vitamin D exacerbates central nervous system autoimmunity by raising T-cell excitatory calcium.
Häusler, D; Torke, S; Peelen, E; Bertsch, T; Djukic, M; Nau, R; Larochelle, C; Zamvil, SS; Brück, W; Weber, MS;
Brain. 2019; 142(9):2737-2755
Originalarbeiten (Zeitschrift)
Therapeutic Plasma Exchange in Multiple Sclerosis and Autoimmune Encephalitis: a Comparative Study of Indication, Efficacy and Safety.
Moser, T; Harutyunyan, G; Karamyan, A; Otto, F; Bacher, C; Chroust, V; Leitinger, M; Novak, HF; Trinka, E; Sellner, J;
Brain Sci. 2019; 9(10):
Originalarbeiten (Zeitschrift)
Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination.
Rivera, FJ; de la Fuente, AG; Zhao, C; Silva, ME; Gonzalez, GA; Wodnar, R; Feichtner, M; Lange, S; Errea, O; Priglinger, E; OSullivan, A; Romanelli, P; Jadasz, JJ; Brachtl, G; Greil, R; Tempfer, H; Traweger, A; Bátiz, LF; Küry, P; Couillard-Despres, S; Franklin, RJM; Aigner, L;
Glia. 2019; 67(8):1510-1525
Originalarbeiten (Zeitschrift)
Pericytes in Multiple Sclerosis.
Rivera, FJ; Hinrichsen, B; Silva, ME
ADV EXP MED BIOL. 2019; 1147: 167-187.
Originalarbeiten (Zeitschrift)
Immunological Aspects of Approved MS Therapeutics.
Rommer, PS; Milo, R; Han, MH; Satyanarayan, S; Sellner, J; Hauer, L; Illes, Z; Warnke, C; Laurent, S; Weber, MS; Zhang, YN; Stuve, O;
FRONT IMMUNOL. 2019; 10: 1564
Repurposing multiple sclerosis drugs: a review of studies in neurological and psychiatric conditions.
Rommer, PS; Sellner, J
DRUG DISCOV TODAY. 2019; 24(7): 1398-1404.
A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis.
Sellner, J; Rommer, PS;
Autoimmun Rev. 2019; 18(3): 255-261.
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.
Uccelli, A; Laroni, A; Brundin, L; Clanet, M; Fernandez, O; Nabavi, SM; Muraro, PA; Oliveri, RS; Radue, EW; Sellner, J; Soelberg Sorensen, P; Sormani, MP; Wuerfel, JT; Battaglia, MA; Freedman, MS;
Trials. 2019; 20(1):263
Originalarbeiten (Zeitschrift)
Month-of-birth-effect in multiple sclerosis in Austria.
Walleczek, NK; Frommlet, F; Bsteh, G; Eggers, C; Rauschka, H; Koppi, S; Assar, H; Ehling, R; Birkl, C; Salhofer-Polanyi, S; Baumgartner, A; Blechinger, S; Buchinger, D; Sellner, J; Kraus, J; Moser, H; Mayr, M; Guger, M; Rathmaier, S; Raber, B; Liendl, H; Hiller, MS; Parigger, S; Morgenstern, G; Kempf, I; Spiss, HK; Meister, B; Heine, M; Cisar, A; Bachler, H; Khalil, M; Fuchs, S; Enzinger, C; Fazekas, F; Leutmezer, F; Berger, T; Kristoferitsch, W; Aboulenein-Djamshidian, F;
Mult Scler. 2019; 25(14): 1870-1877.
Originalarbeiten (Zeitschrift)
Pharmacological Inhibition of Acid Sphingomyelinase Ameliorates Experimental Autoimmune Encephalomyelitis.
Walter, S; Gulbins, E; Halmer, R; Jahromi, NH; Becker, KA; Schottek, A; Blatti, C; Davies, L; Schnoeder, L; Bertsch, T; Engelhardt, B; Fassbender, K;
Neurosignals. 2019; 27(S1): 20-31.
Originalarbeiten (Zeitschrift)
MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein
Baumann, M; Grams, A; Djurdjevic, T; Wendel, EM; Lechner, C; Behring, B; Blaschek, A; Diepold, K; Eisenkolbl, A; Fluss, J; Karenfort, M; Koch, J; Konuskan, B; Leiz, S; Merkenschlager, A; Pohl, D; Schimmel, M; Thiels, C; Kornek, B; Schanda, K; Reindl, M; Rostasy, K
J NEUROL. 2018; 265(4): 845-855.
Originalarbeiten (Zeitschrift)
Why do people search Wikipedia for information on multiple sclerosis?
Brigo, F; Lattanzi, S; Bragazzi, N; Nardone, R; Moccia, M; Lavorgna, L
MULT SCLER RELAT DIS. 2018; 20: 210-214.
Originalarbeiten (Zeitschrift)
Real-life clinical use of natalizumab and fingolimod in Austria.
Guger, M; Enzinger, C; Leutmezer, F; Kraus, J; Kalcher, S; Kvas, E; Berger, T;
Acta Neurol Scand. 2018; 137(2):181-187
Originalarbeiten (Zeitschrift)
Sexual Dysfunction Seems to Trigger Depression in Female Multiple Sclerosis Patients.
Hoesl, KM; Deutsch, M; Wang, R; Roy, S; Winder, K; Niklewski, G; Lee, DH; Linker, RA; Hilz, MJ
EUR NEUROL. 2018; 80(1-2): 34-41.
Originalarbeiten (Zeitschrift)
Human mesenchymal factors induce rat hippocampal- and human neural stem cell dependent oligodendrogenesis.
Jadasz, JJ; Tepe, L; Beyer, F; Samper Agrelo, I; Akkermann, R; Spitzhorn, LS; Silva, ME; Oreffo, ROC; Hartung, HP; Prigione, A; Rivera, FJ; Adjaye, J; Küry, P;
GLIA. 2018; 66(1): 145-160.
Originalarbeiten (Zeitschrift)
Geostatistical Analysis of White Matter Lesions in Multiple Sclerosis Identifies Gender Differences in Lesion Evolution
Marschallinger, R; Muhlau, M; Pongratz, V; Kirschke, JS; Marschallinger, S; Schmidt, P; Sellner, J
FRONT MOL NEUROSCI. 2018; 11: 460
Originalarbeiten (Zeitschrift)
Neutrophil-released enzymes can influence composition of circulating immune complexes in multiple sclerosis
Paryzhak, S; Dumych, T; Mahorivska, I; Boichuk, M; Bila, G; Peshkova, S; Nehrych, T; Bilyy, R
AUTOIMMUNITY. 2018; 51(6): 297-303.
Originalarbeiten (Zeitschrift)
Insular multiple sclerosis lesions are associated with erectile dysfunction
Winder, K; Linker, RA; Seifert, F; Deutsch, M; Engelhorn, T; Dorfler, A; Lee, DH; Hosl, K; Hilz, MJ
J NEUROL. 2018; 265(4): 783-792.
Originalarbeiten (Zeitschrift)
Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients.
Breckwoldt, MO; Gradl, J; Hähnel, S; Hielscher, T; Wildemann, B; Diem, R; Platten, M; Wick, W; Heiland, S; Bendszus, M;
J Neurol. 2017; 264(2):341-349
Originalarbeiten (Zeitschrift)
The CD24 surface antigen in neural development and disease.
Gilliam, DT; Menon, V; Bretz, NP; Pruszak, J;
Neurobiol Dis. 2017; 99:133-144
From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.
Harrer, A; Pilz, G; Oppermann, K; Sageder, M; Afazel, S; Haschke-Becher, E; Rispens, T; de Vries, A; McCoy, M; Stevanovic, V; Hitzl, W; Trinka, E; Kraus, J; Sellner, J; Wipfler, P;
Clin Immunol. 2017; 176: 87-93.
Originalarbeiten (Zeitschrift)
Fingolimod initiation in multiple sclerosis patients is associated with potential beneficial cardiovascular autonomic effects.
Hilz, MJ; Wang, RH; Leal, CD; Liu, M; Canavese, F; Roy, S; Hosl, KM; Winder, K; Lee, DH; Linker, RA
THER ADV NEUROL DISO. 2017; 10(4): 191-209.
Originalarbeiten (Zeitschrift)
Causes of death in critically ill multiple sclerosis patients.
Karamyan, A; Brandtner, H; Grinzinger, S; Chroust, V; Bacher, C; Otto, F; Reisp, M; Hauer, L; Sellner, J;
Acta Neurol Scand. 2017; 136(4):305-309
Originalarbeiten (Zeitschrift)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban, X; Hauser, SL; Kappos, L; Arnold, DL; Bar-Or, A; Comi, G; de Seze, J; Giovannoni, G; Hartung, HP; Hemmer, B; Lublin, F; Rammohan, KW; Selmaj, K; Traboulsee, A; Sauter, A; Masterman, D; Fontoura, P; Belachew, S; Garren, H; Mairon, N; Chin, P; Wolinsky, JS;
N Engl J Med. 2017; 376(3):209-220
Originalarbeiten (Zeitschrift)
Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.
Huss, AM; Halbgebauer, S; Öckl, P; Trebst, C; Spreer, A; Borisow, N; Harrer, A; Brecht, I; Balint, B; Stich, O; Schlegel, S; Retzlaff, N; Winkelmann, A; Roesler, R; Lauda, F; Yildiz, Ö; Voß, E; Muche, R; Rauer, S; Bergh, FT; Otto, M; Paul, F; Wildemann, B; Kraus, J; Ruprecht, K; Stangel, M; Buttmann, M; Zettl, UK; Tumani, H;
J Neurol. 2016; 263(12):2499-2504
Originalarbeiten (Zeitschrift)
Infectious Mononucleosis Triggers Generation of IgG Auto-Antibodies against Native Myelin Oligodendrocyte Glycoprotein
Kakalacheva, K; Regenass, S; Wiesmayr, S; Azzi, T; Berger, C; Dale, RC; Brilot, F; Munz, C; Rostasy, K; Nadal, D; Lunemann, JD
VIRUSES-BASEL. 2016; 8(2):
Originalarbeiten (Zeitschrift)
Critical Illness in Patients with Multiple Sclerosis: A Matched Case-Control Study.
Karamyan, A; Dünser, MW; Wiebe, DJ; Pilz, G; Wipfler, P; Chroust, V; Novak, HF; Hauer, L; Trinka, E; Sellner, J;
PLoS One. 2016; 11(5):e0155795
Originalarbeiten (Zeitschrift)
B-mode transorbital ultrasononography for the diagnosis of acute optic neuritis. A systematic review.
Lochner, P; Leone, MA; Coppo, L; Nardone, R; Zedde, ML; Cantello, R; Brigo, F;
Clin Neurophysiol. 2016; 127(1): 803-809.
Originalarbeiten (Zeitschrift)
A MS-lesion pattern discrimination plot based on geostatistics.
Marschallinger, R; Schmidt, P; Hofmann, P; Zimmer, C; Atkinson, PM; Sellner, J; Trinka, E; Mühlau, M;
BRAIN BEHAV. 2016; 6(3): e00430
Originalarbeiten (Zeitschrift)
Neuroanatomic Correlates of Female Sexual Dysfunction in Multiple Sclerosis.
Winder, K; Linker, RA; Seifert, F; Deutsch, M; Engelhorn, T; Dörfler, A; Lee, DH; Hoesl, KM; Hilz, MJ;
Ann Neurol. 2016; 80(4): 490-498.
Originalarbeiten (Zeitschrift)
Energy metabolism in neuroblastoma and Wilms tumor.
Aminzadeh, S; Vidali, S; Sperl, W; Kofler, B; Feichtinger, RG;
Transl Pediatr. 2015; 4(1):20-32
Wikipedia and neurological disorders.
Brigo, F; Igwe, SC; Nardone, R; Lochner, P; Tezzon, F; Otte, WM
J Clin Neurosci. 2015; 22(7):1170-1172
Diagnostic and Prognostic Value of High-sensitivity Cardiac Troponin T in Patients with Syncope.
Christ, M; Geier, F; Popp, S; Singler, K; Smolarsky, A; Bertsch, T; Müller, C; Greve, Y;
Am J Med. 2015; 128(2): 161-170.e1.
Originalarbeiten (Zeitschrift)
Variables related to working capability among Swiss patients with multiple sclerosis--a cohort study.
Findling, O; Baltisberger, M; Jung, SM; Kamm, CP; Mattle, HP; Sellner, J
PLoS One. 2015; 10(4):e0121856
Originalarbeiten (Zeitschrift)
High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.
Harrer, A; Pilz, G; Wipfler, P; Oppermann, K; Sellner, J; Hitzl, W; Haschke-Becher, E; Afazel, S; Rispens, T; van der Kleij, D; Trinka, E; Kraus, J;
Clin Exp Immunol. 2015; 180(3):383-392
Originalarbeiten (Zeitschrift)
Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Harrer, A; Wipfler, P; Pilz, G; Oppermann, K; Haschke-Becher, E; Afazel, S; Kraus, J; Trinka, E; Sellner, J;
Int J Mol Sci. 2015; 16(9): 21832-21845.
Originalarbeiten (Zeitschrift)
Oligoclonal bands predict multiple sclerosis in children with optic neuritis.
Heussinger, N; Kontopantelis, E; Gburek-Augustat, J; Jenke, A; Vollrath, G; Korinthenberg, R; Hofstetter, P; Meyer, S; Brecht, I; Kornek, B; Herkenrath, P; Schimmel, M; Wenner, K; Häusler, M; Lutz, S; Karenfort, M; Blaschek, A; Smitka, M; Karch, S; Piepkorn, M; Rostasy, K; Lücke, T; Weber, P; Trollmann, R; Klepper, J; Häussler, M; Hofmann, R; Weissert, R; Merkenschlager, A; Buttmann, M;
Ann Neurol. 2015; 77(6):1076-1082
Originalarbeiten (Zeitschrift)
Bladder and Bowel Dysfunction Is Common in Both Men and Women with Mutation of the ABCD1 Gene for X-Linked Adrenoleukodystrophy.
Hofereiter, J; Smith, MD; Seth, J; Tudor, KI; Fox, Z; Emmanuel, A; Murphy, E; Lachmann, RH; Panicker, J;
JIMD Rep. 2015; 22:77-83
Originalarbeiten (Zeitschrift)
Fingolimod induces neuroprotective factors in human astrocytes.
Hoffmann, FS; Hofereiter, J; Rübsamen, H; Melms, J; Schwarz, S; Faber, H; Weber, P; Pütz, B; Loleit, V; Weber, F; Hohlfeld, R; Meinl, E; Krumbholz, M;
J Neuroinflammation. 2015; 12:184
Originalarbeiten (Zeitschrift)
Fibroblast growth factor signalling in multiple sclerosis: inhibition of myelination and induction of pro-inflammatory environment by FGF9.
Lindner, M; Thümmler, K; Arthur, A; Brunner, S; Elliott, C; McElroy, D; Mohan, H; Williams, A; Edgar, JM; Schuh, C; Stadelmann, C; Barnett, SC; Lassmann, H; Mücklisch, S; Mudaliar, M; Schaeren-Wiemers, N; Meinl, E; Linington, C;
Brain. 2015; 138(Pt 7): 1875-1893.
Originalarbeiten (Zeitschrift)
Web search behavior for multiple sclerosis: An infodemiological study
Brigo, F; Lochner, P; Tezzon, F; Nardone, R
MULT SCLER RELAT DIS. 2014; 3(4): 440-443.
Originalarbeiten (Zeitschrift)
Antimyelin antibodies as predictors of disability after clinically isolated syndrome.
Findling, O; Durot, I; Weck, A; Jung, S; Kamm, CP; Greeve, I; Mattle, HP; Sellner, J;
Int J Neurosci. 2014; 124(8): 567-572.
Originalarbeiten (Zeitschrift)
High-dose intravenous interferon-beta in multiple sclerosis patients with high-titer neutralizing antibodies (HINABS II) - A pilot study.
Hegen, H; Guger, M; Harrer, A; Hoelzl, M; Kraus, J; Skrobal, A; Schautzer, F; Schmidegg, S; Schocke, M; Deisenhammer, F;
Mult Scler Relat Disord. 2014; 3(2):220-226
Originalarbeiten (Zeitschrift)
Usability and Potential of Geostatistics for Spatial Discrimination of Multiple Sclerosis Lesion Patterns
Marschallinger, R; Golaszewski, SM; Kunz, AB; Kronbichler, M; Ladurner, G; Hofmann, P; Trinka, E; McCoy, M; Kraus, J
J NEUROIMAGING. 2014; 24(3): 278-286.
Originalarbeiten (Zeitschrift)
A routine-qualified flow cytometric method for the identification of multiple sclerosis patients with reduced therapy efficiency under natalizumab
Oppermann, K; Harrer, A; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Sellner, J; Deisenhammer, F; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2014; 38(1): 17-23.
Originalarbeiten (Zeitschrift)
FADD is upregulated in relapsing remitting multiple sclerosis.
Reuss, R; Mistarz, M; Mirau, A; Kraus, J; Bodeker, RH; Oschmann, P
NEUROIMMUNOMODULAT. 2014; 21(5): 221-225.
Originalarbeiten (Zeitschrift)
What to expect after natalizumab cessation in a real-life setting.
Salhofer-Polanyi, S; Baumgartner, A; Kraus, J; Maida, E; Schmied, M; Leutmezer, F
Acta Neurol Scand. 2014; 130(2):97-102
Originalarbeiten (Zeitschrift)
Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models.
Schuh, C; Wimmer, I; Hametner, S; Haider, L; Van Dam, AM; Liblau, RS; Smith, KJ; Probert, L; Binder, CJ; Bauer, J; Bradl, M; Mahad, D; Lassmann, H;
Acta Neuropathol. 2014; 128(2): 247-266.
Originalarbeiten (Zeitschrift)
Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?
Wipfler, P; Harrer, A; Pilz, G; Oppermann, K; Afazel, S; Haschke-Becher, E; Sellner, J; Trinka, E; Kraus, J;
Acta Neurol Scand. 2014; 129(3):e12-e15
Originalarbeiten (Zeitschrift)
How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Fazekas, F; Bajenaru, O; Berger, T; Fabjan, TH; Ledinek, AH; Jakab, G; Komoly, S; Kobys, T; Kraus, J; Kurča, E; Kyriakides, T; Lisý, L; Milanov, I; Nehrych, T; Moskovko, S; Panayiotou, P; Jazbec, SŠ; Sokolova, L; Taláb, R; Traykov, L; Turčáni, P; Vass, K; Vella, N; Voloshyná, N; Havrdová, E;
Front Neurol. 2013; 4: 10
Originalarbeiten (Zeitschrift)
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
Harrer, A; Tumani, H; Niendorf, S; Lauda, F; Geis, C; Weishaupt, A; Kleinschnitz, C; Rauer, S; Kuhle, J; Stangel, M; Weber, F; Uhr, M; Linnebank, M; Wildemann, B; Jarius, S; Guger, M; Ayzenberg, I; Chan, A; Zettl, U; Wiendl, H; Pilz, G; Hitzl, W; Weber, JR; Kraus, J;
Mult Scler. 2013; 19(9):1209-1212
Originalarbeiten (Zeitschrift)
Predicting multiple sclerosis following isolated optic neuritis in children.
Heussinger, N; Kontopantelis, E; Rompel, O; Paulides, M; Trollmann, R;
Eur J Neurol. 2013; 20(9):1292-1296
Originalarbeiten (Zeitschrift)
Mesenchymal stem cell conditioning promotes rat oligodendroglial cell maturation.
Jadasz, JJ; Kremer, D; Göttle, P; Tzekova, N; Domke, J; Rivera, FJ; Adjaye, J; Hartung, HP; Aigner, L; Küry, P;
PLoS One. 2013; 8(8):e71814
Originalarbeiten (Zeitschrift)
Harmonization of European neurology education: the junior doctor"s perspective.
Macerollo, A; Struhal, W; Sellner, J;
Neurology. 2013; 81(18): 1626-1629.
TRAF2 is upregulated in relapsing-remitting multiple sclerosis.
Reuß, R; Mirau, A; Mistarz, M; Kraus, J; Bödeker, RH; Oschmann, P;
Neuroimmunomodulation. 2013; 20(3):177-183
Originalarbeiten (Zeitschrift)
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Sellner, J; Koczi, W; Harrer, A; Oppermann, K; Obregon-Castrillo, E; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Clin Exp Immunol. 2013; 173(3):381-389
Originalarbeiten (Zeitschrift)
Circadian rhythmicity of inflammatory serum parameters: a neglected issue in the search of biomarkers in multiple sclerosis.
Wipfler, P; Heikkinen, A; Harrer, A; Pilz, G; Kunz, A; Golaszewski, SM; Reuss, R; Oschmann, P; Kraus, J;
J Neurol. 2013; 260(1):221-227
Originalarbeiten (Zeitschrift)
Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.
Fazekas, F; Berger, T; Fabjan, TH; Ledinek, AH; Jakab, G; Komoly, S; Kraus, J; Kurča, E; Kyriakides, T; Lisý, L; Milanov, I; Panayiotou, P; Jazbec, SS; Taláb, R; Traykov, L; Turčáni, P; Vass, K; Vella, N; Havrdová, E;
Wien Med Wochenschr. 2012; 162(15-16): 354-366.
Flow cytometry and drug monitoring of natalizumab saturation of immune cells in multiple sclerosis
Harrer, A; Oppermann, K; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, L; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2012; 36(6): 377-382.
Originalarbeiten (Zeitschrift)
Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
Harrer, A; Pilz, G; Einhaeupl, M; Oppermann, K; Hitzl, W; Wipfler, P; Sellner, J; Golaszewski, S; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
PLoS One. 2012; 7(2):e31784
Originalarbeiten (Zeitschrift)
Noninvasive molecular imaging of neuroinflammation.
Jacobs, AH; Tavitian, B;
J Cereb Blood Flow Metab. 2012; 32(7):1393-1415
The remyelination Philosopher"s Stone: stem and progenitor cell therapies for multiple sclerosis.
Jadasz, JJ; Aigner, L; Rivera, FJ; Küry, P;
Cell Tissue Res. 2012; 349(1):331-347
p57kip2 regulates glial fate decision in adult neural stem cells.
Jadasz, JJ; Rivera, FJ; Taubert, A; Kandasamy, M; Sandner, B; Weidner, N; Aktas, O; Hartung, HP; Aigner, L; Küry, P;
Development. 2012; 139(18):3306-3315
Originalarbeiten (Zeitschrift)
Overview of laboratory methods to monitor innovative treatment regimens in multiple sclerosis
Kraus, J; Pilz, G; Wipfler, P; Holl, B; Oppermann, K; Golaszewski, SM; Harrer, A
LABORATORIUMSMEDIZIN. 2012; 36(6): 389-396.
Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity.
Leussink, VI; Husseini, L; Warnke, C; Broussalis, E; Hartung, HP; Kieseier, BC;
Ther Adv Neurol Disord. 2012; 5(5):255-266
Originalarbeiten (Zeitschrift)
Serum from interferon-beta-1b-treated patients with early multiple sclerosis stabilizes the blood-brain barrier in vitro
Muller, M; Frese, A; Nassenstein, I; Hoppen, M; Marziniak, M; Ringelstein, EB; Kim, KS; Schabitz, WR; Kraus, J
MULT SCLER J. 2012; 18(2): 236-239.
Originalarbeiten (Zeitschrift)
Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.
Pilz, G; Harrer, A; Oppermann, K; Wipfler, P; Golaszewski, S; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Mult Scler. 2012; 18(4):506-509
Originalarbeiten (Zeitschrift)
Future relevance of CSF biomarkers in modern MS treatment
Pilz, G; Wipfler, P; Harrer, A; Holl, B; Oppermann, K; Golaszewski, SM; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2012; 36(6): 383-388.
Originalarbeiten (Zeitschrift)
Adult mesenchymal stem cell therapy for myelin repair in multiple sclerosis.
Rivera, FJ; Aigner, L;
Biol Res. 2012; 45(3):257-268
Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell response
Seifert, CL; Wegner, C; Sprenger, T; Weber, MS; Bruck, W; Hemmer, B; Sellner, J
MULT SCLER J. 2012; 18(7): 1045-1049.
Originalarbeiten (Zeitschrift)
Mesenchymal stem cells prime proliferating adult neural progenitors toward an oligodendrocyte fate.
Steffenhagen, C; Dechant, FX; Oberbauer, E; Furtner, T; Weidner, N; Küry, P; Aigner, L; Rivera, FJ;
Stem Cells Dev. 2012; 21(11):1838-1851
Originalarbeiten (Zeitschrift)
Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Weber, MS; Menge, T; Lehmann-Horn, K; Kronsbein, HC; Zettl, U; Sellner, J; Hemmer, B; Stuve, O
CURR PHARM DESIGN. 2012; 18(2): 209-219.
Selective amygdalo-hippocampectomy as a potential trigger for disease progression in multiple sclerosis.
Ehling, R; Dobesberger, J; Unterberger, I; Benke, T; Gotwald, T; Ortler, M; Berger, T; Trinka, E;
Clin Neurol Neurosurg. 2011; 113(2): 136-138.
Trunk sway in mildly disabled multiple sclerosis patients with and without balance impairment
Findling, O; Sellner, J; Meier, N; Allum, JHJ; Vibert, D; Lienert, C; Mattle, HP
EXP BRAIN RES. 2011; 213(4): 363-370.
Originalarbeiten (Zeitschrift)
Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.
Harrer, A; Wipfler, P; Einhaeupl, M; Pilz, G; Oppermann, K; Hitzl, W; Afazel, S; Haschke-Becher, E; Strasser, P; Trinka, E; Kraus, J;
J Neuroimmunol. 2011; 234(1-2):148-154
Originalarbeiten (Zeitschrift)
Patient-reported quality of life in multiple sclerosis differs between cultures and countries: a cross-sectional Austrian-German-Polish study.
Pluta-Fuerst, A; Petrovic, K; Berger, T; Fryze, W; Fuchs, S; Gold, R; Kozubski, W; Ladurner, G; Petereit, H; Potemkowski, A; Rieckmann, P; Sailer, M; Szczudlik, A; Vass, K; Weber, T; Zakrzewska-Pniewska, B; Fazekas, F;
MULT SCLER J. 2011; 17(4): 47-86.
Originalarbeiten (Zeitschrift)
The increasing incidence and prevalence of female multiple sclerosis-A critical analysis of potential environmental factors
Sellner, J; Kraus, J; Awad, A; Milo, R; Hemmer, B; Stuve, O
AUTOIMMUN REV. 2011; 10(8): 495-502.
Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options.
Wipfler, P; Harrer, A; Pilz, G; Oppermann, K; Trinka, E; Kraus, J;
Drug Discov Today. 2011; 16(1-2):8-21
Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
Wipfler, P; Oppermann, K; Pilz, G; Afazel, S; Haschke-Becher, E; Harrer, A; Huemer, M; Kunz, A; Golaszewski, S; Staffen, W; Ladurner, G; Kraus, J;
Mult Scler. 2011; 17(1):16-23
Originalarbeiten (Zeitschrift)
ADAM12 is expressed by astrocytes during experimental demyelination.
Baertling, F; Kokozidou, M; Pufe, T; Clarner, T; Windoffer, R; Wruck, CJ; Brandenburg, LO; Beyer, C; Kipp, M;
Brain Res. 2010; 1326:1-14
Originalarbeiten (Zeitschrift)
Decision-making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS).
Fazekas, F; Baumhackl, U; Berger, T; Deisenhammer, F; Fuchs, S; Kristoferitsch, W; Ladurner, G; Soukop, W; Wimmer, G; Vass, K;
Eur J Neurol. 2010; 17(6):852-860
Originalarbeiten (Zeitschrift)
Fine mapping of T-cell immunoglobulin mucin domain gene 1 failed to detect a significant association with multiple sclerosis.
Grabmer, C; Nachbauer, W; Schanda, K; Feurle, P; Loacker, K; Scholz, E; Schennach, H; Berger, T; Reindl, M; Gassner, C;
Tissue Antigens. 2010; 75(3): 235-241.
Originalarbeiten (Zeitschrift)
A 76-year-old woman with paraplegia.
Rémi, J; Pfefferkorn, T; König, FB; Lassmann, H; Brück, W; Holtmannspötter, M; Straube, A; Kretzschmar, HA; Schüller, U;
Brain Pathol. 2010; 20(2):507-510
EFNS guidelines on diagnosis and management of neuromyelitis optica.
Sellner, J; Boggild, M; Clanet, M; Hintzen, RQ; Illes, Z; Montalban, X; Du Pasquier, RA; Polman, CH; Sorensen, PS; Hemmer, B;
Eur J Neurol. 2010; 17(8): 1019-1032.
Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses.
Sellner, J; Cepok, S; Kalluri, SR; Nestler, A; Kleiter, I; Kümpfel, T; Linker, R; Melms, A; Menge, T; Tumani, H; Paul, F; Hemmer, B; Berthele, A;
Neurochem Int. 2010; 57(6): 662-667.
Originalarbeiten (Zeitschrift)
[Radiologically isolated syndrome: multiple sclerosis based solely on MRI findings?].
Sellner, J; Schirmer, L; Hemmer, B; Mühlau, M;
Nervenarzt. 2010; 81(10): 1208-1217.
The radiologically isolated syndrome: take action when the unexpected is uncovered?
Sellner, J; Schirmer, L; Hemmer, B; Mühlau, M;
J Neurol. 2010; 257(10): 1602-1611.
The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon?
Sellner, J; Weber, MS; Vollmar, P; Mattle, HP; Hemmer, B; Stüve, O;
CNS Neurosci Ther. 2010; 16(6): 362-373.
Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease.
Weber, MS; Benkhoucha, M; Lehmann-Horn, K; Hertzenberg, D; Sellner, J; Santiago-Raber, ML; Chofflon, M; Hemmer, B; Zamvil, SS; Lalive, PH;
PLoS One. 2010; 5(12): e16009
Originalarbeiten (Zeitschrift)
Obliterating intracranial vasculopathy mimicking multiple sclerosis.
Boentert, M; Kraus, J; Kloska, S; Dittrich, R; Nabavi, DG; Niederstadt, T; Ringelstein, EB; Kiefer, R;
ACTA NEUROL SCAND. 2009; 120(1): 68-71.
Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study.
Gneiss, C; Koudouovoh-Tripp, PM; Ropele, S; Gotwald, T; Ehling, R; Lutterotti, A; Aichner, F; Ladurner, G; Eggers, C; Schautzer, F; Künz, B; Millonig, A; Aspeck, E; Reindl, M; Berger, T; Fazekas, F; Deisenhammer, F;
MULT SCLER. 2009; 15(12): 1481-1488.
Originalarbeiten (Zeitschrift)
[Cognitive dysfunction as a hidden multiple sclerosis related symptom relevant for an expert appraisal].
Kraus, J; Lohmann, H; Evers, S;
FORTSCHR NEUROL PSYC. 2009; 77(1): 38-43.
Modafinil effects in multiple sclerosis patients with fatigue.
Lange, R; Volkmer, M; Heesen, C; Liepert, J;
J Neurol. 2009; 256(4): 64-50.
Originalarbeiten (Zeitschrift)
Mesenchymal stem cells promote oligodendroglial differentiation in hippocampal slice cultures.
Rivera, FJ; Siebzehnrubl, FA; Kandasamy, M; Couillard-Despres, S; Caioni, M; Poehler, AM; Berninger, B; Sandner, B; Bogdahn, U; Goetz, M; Bluemcke, I; Weidner, N; Aigner, L;
Cell Physiol Biochem. 2009; 24(3-4):317-324
Originalarbeiten (Zeitschrift)
Diagnostic workup of patients with acute transverse myelitis: spectrum of clinical presentation, neuroimaging and laboratory findings.
Sellner, J; Lüthi, N; Schüpbach, WM; Gebhardt, A; Findling, O; Schroth, G; Mattle, HP; Nedeltchev, K;
Spinal Cord. 2009; 47(4):312-317
Originalarbeiten (Zeitschrift)
Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro.
Kraus, J; Voigt, K; Schuller, AM; Scholz, M; Kim, KS; Schilling, M; Schäbitz, WR; Oschmann, P; Engelhardt, B;
MULT SCLER. 2008; 14(6): 843-852.
Originalarbeiten (Zeitschrift)
Atorvastatin does not alter serum levels of sCD95 and sCD95L in multiple sclerosis.
Sellner, J; Greeve, I; Findling, O; Grandgirard, D; Leib, SL; Mattle, HP;
Clin Exp Immunol. 2008; 152(2):280-284
Originalarbeiten (Zeitschrift)
Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis.
Sellner, J; Greeve, I; Findling, O; Kamm, CP; Minten, C; Engelhardt, B; Grandgirard, D; Leib, SL; Mattle, HP;
Neurochem Int. 2008; 53(1-2):17-21
Originalarbeiten (Zeitschrift)
Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis.
Sellner, J; Greeve, I; Mattle, HP;
Mult Scler. 2008; 14(7):981-984
Originalarbeiten (Zeitschrift)
Acute partial transverse myelitis: risk factors for conversion to multiple sclerosis.
Sellner, J; Lüthi, N; Bühler, R; Gebhardt, A; Findling, O; Greeve, I; Mattle, HP;
Eur J Neurol. 2008; 15(4):398-405
Originalarbeiten (Zeitschrift)
Tumefactive lesion in multiple sclerosis.
Findling, O; Sellner, J; Ozdoba, C; Arnold, M;
Acta Neurol Belg. 2007; 107(4):134
Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort.
Greeve, I; Sellner, J; Lauterburg, T; Walker, U; Rösler, KM; Mattle, HP;
Acta Neurol Scand. 2007; 116(4):207-210
Originalarbeiten (Zeitschrift)
Acute myelopathy of unknown aetiology: a follow-up investigation.
Nowak, DA; Mutzenbach, S; Topka, H;
J Clin Neurosci. 2006; 13(3):339-342
Originalarbeiten (Zeitschrift)
Differences in cerebral activation patterns in idiopathic inflammatory demyelination using the paced visual serial addition task: an fMRI study.
Rachbauer, D; Kronbichler, M; Ropele, S; Enzinger, C; Fazekas, F;
J Neurol Sci. 2006; 244(1-2):11-16
Originalarbeiten (Zeitschrift)
CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
Chatzimanolis, N; Kraus, J; Bauer, R; Engelhardt, B; Bregenzer, T; Kuehne, BS; Tofighi, J; Laske, C; Stolz, E; Blaes, F; Voigt, K; Traupe, H; Kaps, M; Oschmann, P;
ACTA NEUROL SCAND. 2004; 110(6): 377-385.
Originalarbeiten (Zeitschrift)
Interferon-beta(1b) leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis
Kraus, J; Bauer, R; Chatzimanolis, N; Engelhardt, B; Tofighi, J; Bregenzer, T; Kuehne, BS; Stolz, E; Blaes, F; Morgen, K; Traupe, H; Kaps, M; Oschmann, P
J NEUROL. 2004; 251(4): 464-472.
Originalarbeiten (Zeitschrift)
Acute myelopathy. Retrospective clinical, laboratory, MRI and outcome analysis of 49 cases.
Nowak, DA; Mutzenbach, S; Fuchs, HH;
J Clin Neurosci. 2004; 11(2):14-52
Originalarbeiten (Zeitschrift)
[Multiple sclerosis: imaging, diagnostic criteria and differential diagnosis].
Harting, I; Sellner, J; Meyding-Lamadé, U; Sartor, K;
Rofo. 2003; 175(5):613-622
A diffusion tensor MRI study of basal ganglia from patients with ADEM.
Holtmannspötter, M; Inglese, M; Rovaris, M; Rocca, MA; Codella, M; Filippi, M;
J Neurol Sci. 2003; 206(1):27-30
Originalarbeiten (Zeitschrift)
Cell surface bound and soluble adhesion molecules in CSF and blood in multiple sclerosis: correlation with MRI-measures of subclinical disease severity and activity.
Kraus, J; Engelhardt, B; Chatzimanolis, N; Bauer, R; Tofighi, J; Kuehne, BS; Laske, C; Stolz, E; Frielinghaus, P; Schaefer, C; Blaes, F; Traupe, H; Kaps, M; Oschmann, P;
J Neuroimmunol. 2002; 122(1-2): 17-85.
Originalarbeiten (Zeitschrift)
Serum cytokine levels do not correlate with disease activity and severity assessed by brain MRI in multiple sclerosis.
Kraus, J; Kuehne, BS; Tofighi, J; Frielinghaus, P; Stolz, E; Blaes, F; Laske, C; Engelhardt, B; Traupe, H; Kaps, M; Oschmann, P;
Acta Neurol Scand. 2002; 105(4): 300-308.
Originalarbeiten (Zeitschrift)
Contribution of cervical cord MRI and brain magnetization transfer imaging to the assessment of individual patients with multiple sclerosis: a preliminary study.
Rovaris, M; Holtmannspötter, M; Rocca, MA; Iannucci, G; Codella, M; Viti, B; Campi, A; Comi, G; Yousry, TA; Filippi, M;
Mult Scler. 2002; 8(1):52-58
Originalarbeiten (Zeitschrift)
Cognitive function and fMRI in patients with multiple sclerosis: evidence for compensatory cortical activation during an attention task.
Staffen, W; Mair, A; Zauner, H; Unterrainer, J; Niederhofer, H; Kutzelnigg, A; Ritter, S; Golaszewski, S; Iglseder, B; Ladurner, G
Brain. 2002; 125(Pt 6):1275-1282
Originalarbeiten (Zeitschrift)
Glycosylation processing inhibition by castanospermine prevents experimental autoimmune encephalomyelitis by interference with IL-2 receptor signal transduction
Walter, S; Fassbender, K; Gulbins, E; Liu, Y; Rieschel, M; Herten, M; Bertsch, T; Engelhardt, B
J NEUROIMMUNOL. 2002; 132(1-2): 1-10.
Originalarbeiten (Zeitschrift)
Induction of sTNF-R1 and sTNF-R2 by interferon beta-1b in correlation with clinical and MRI activity.
Laske, C; Oschmann, P; Tofighi, J; Kuehne, SB; Diehl, H; Bregenzer, T; Kraus, J; Bauer, R; Chatzimanolis, N; Kern, A; Traupe, H; Kaps, M;
Acta Neurol Scand. 2001; 103(2): 105-113.
Originalarbeiten (Zeitschrift)
Soluble and cell surface ICAM-3 in blood and cerebrospinal fluid of patients with multiple sclerosis: influence of methylprednisolone treatment and relevance as markers for disease activity.
Kraus, J; Oschmann, P; Engelhardt, B; Bauer, R; Schiel, C; Kern, A; Stolz, E; Traupe, A; Dorndorf, W;
Acta Neurol Scand. 2000; 101(2): 135-139.
Originalarbeiten (Zeitschrift)
CD45RA+ ICAM-3+ lymphocytes in cerebrospinal fluid and blood as markers of disease activity in patients with multiple sclerosis.
Kraus, J; Oschmann, P; Engelhardt, B; Stolz, E; Kuehne, BS; Laske, C; Schaefer, C; Traupe, H; Kaps, M;
Acta Neurol Scand. 2000; 102(5): 326-332.
Originalarbeiten (Zeitschrift)
Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis.
Kraus, J; Oschmann, P; Engelhardt, B; Schiel, C; Hornig, C; Bauer, R; Kern, A; Traupe, H; Dorndorf, W;
Acta Neurol Scand. 1998; 98(2): 102-109.
Originalarbeiten (Zeitschrift)
Preliminary clinical observations on a new trigeminal reflex: the trigemino-cervical reflex.
DiLazzaro, V; Restuccia, D; Nardone, R; Tartaglione, T; Quartarone, A; Tonali, P; Rothwell, JC
Neurology. 1996; 46(2):479-485
Originalarbeiten (Zeitschrift)
[The diagnostic value of nuclear magnetic resonance tomography, multimodal evoked potentials and cerebrospinal fluid examination in multiple sclerosis].
Staffen, W; Trinka, E; Ladurner, G;
Nervenarzt. 1993; 64(4): 226-232.
Originalarbeiten (Zeitschrift)